The new SCAI initiative brings optimism for a population that has seen little innovation or changes to treatment paradigms in ...

The trial’s findings will dampen enthusiasm for the drug in stroke recovery, though research questions remain, one expert ...

In 2023, there were 437 million disability-adjusted life-years lost from cardiovascular disease, up from 320 million in 1990.

Juan Granada and Sammy Elmariah discuss challenges that impact treatment plans for patients with severe aortic stenosis.

The drug met primary safety and efficacy outcomes, with full results to be presented at the AHA Scientific Sessions.

The paper aims to increase awareness of cardiac long COVID and make management quicker, more accurate, and safer.

The two observational studies have limitations, including use of older GLP-1s, but still point to the strengths of bariatric ...

By beginning in hospital, researchers hope to kickstart LDL-lowering with a drug class that has been difficult to access.

EchoNet-Measurements shows promise against sonographers and in an external validation set but needs prospective study.

Roughly one out of every two people who start taking semaglutide (Wegovy; Novo Nordisk) to lose weight will stop taking the ...

The deep-learning model used the whole “breast architecture,” not just calcification, to predict MACE risk in middle-aged ...

SCAD was common and frequently misdiagnosed, especially in women, which can be problematic for treatment decisions.